Historical salary details - Mr. David M. Mott, Chairman of the Board, Adaptimmune Therapeutics Plc - ADR
Mr. David M. Mott is the Chairman of the Board of Adaptimmune Therapeutics Plc - ADR. They also hold 3 other positions in Mersana Therapeutics Inc, Novavax, Inc. and Ardelyx Inc.
Mr. David M. Mott
Chairman of the Board
-
Gross Remuneration
-
Current Company
Adaptimmune Therapeutics Plc - ADR
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | - | - |
| 2024 | Mersana Therapeutics Inc | Chairman of the Board | - | - |
| 2024 | Novavax, Inc. | Independent Director | - | - |
| 2024 | Ardelyx Inc | Chairman of the Board | - | - |
| 2023 | Mersana Therapeutics Inc | Chairman of the Board | 329.9 K | 65.6 % |
| 2023 | Ardelyx Inc | Chairman of the Board | 249.9 K | 76.4 % |
| 2023 | Novavax, Inc. | Independent Director | 187.5 K | -50.7 % |
| 2023 | Adaptimmune Therapeutics Plc - ADR | - | 174.8 K | -16.2 % |
| 2022 | Novavax, Inc. | Independent Director | 380.6 K | -4.8 % |
| 2022 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | 208.5 K | -29.9 % |
| 2022 | Mersana Therapeutics Inc | Chairman of the Board | 199.2 K | -39.6 % |
| 2022 | Ardelyx Inc | Chairman of the Board | 141.7 K | -43.2 % |
| 2021 | Novavax, Inc. | Independent Director | 399.6 K | -45.1 % |
| 2021 | Mersana Therapeutics Inc | Chairman of the Board | 330.0 K | 53.7 % |
| 2021 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | 297.4 K | 5.3 % |
| 2021 | Ardelyx Inc | Chairman of the Board | 249.4 K | -58.2 % |
| 2020 | Novavax, Inc. | Independent Director | 727.3 K | - |
| 2020 | Ardelyx Inc | Chairman of the Board | 597.1 K | 223.6 % |
| 2020 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | 282.5 K | 117.6 % |
| 2020 | Mersana Therapeutics Inc | Chairman of the Board | 214.8 K | 43.9 % |
| 2019 | Ardelyx Inc | Chairman of the Board | 184.5 K | 45.0 % |
| 2019 | Mersana Therapeutics Inc | Chairman of the Board | 149.2 K | -7.0 % |
| 2019 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | 129.8 K | -42.4 % |
| 2018 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | 225.5 K | 56.0 % |
| 2018 | Mersana Therapeutics Inc | Chairman of the Board | 160.4 K | 319.9 % |
| 2018 | Ardelyx Inc | Chairman of the Board | 127.2 K | -1.0 % |
| 2017 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | 144.5 K | 2.5 % |
| 2017 | Ardelyx Inc | Chairman of the Board | 128.6 K | -24.3 % |
| 2017 | Mersana Therapeutics Inc | Chairman of the Board | 38.2 K | - |
| 2016 | Ardelyx Inc | Chairman of the Board | 169.7 K | -23.4 % |
| 2016 | Adaptimmune Therapeutics Plc - ADR | Chairman of the Board | 141.1 K | - |
| 2016 | Mersana Therapeutics Inc | Chairman of the Board | - | - |
| 2015 | Ardelyx Inc | Chairman of the Board | 221.5 K | 160.6 % |
| 2015 | Adaptimmune Therapeutics Plc - ADR | Independent Director | - | - |
| 2014 | Ardelyx Inc | Chairman of the Board | 85 K | - |
| 2014 | Adaptimmune Therapeutics Plc - ADR | Independent Director | - | - |
| 2013 | Ardelyx Inc | Chairman of the Board | - | - |